EA200100662A1 - METHOD AND COMPOSITION FOR MAINTAINING AND RESTORING INTESTINITY INTEGRITY - Google Patents

METHOD AND COMPOSITION FOR MAINTAINING AND RESTORING INTESTINITY INTEGRITY

Info

Publication number
EA200100662A1
EA200100662A1 EA200100662A EA200100662A EA200100662A1 EA 200100662 A1 EA200100662 A1 EA 200100662A1 EA 200100662 A EA200100662 A EA 200100662A EA 200100662 A EA200100662 A EA 200100662A EA 200100662 A1 EA200100662 A1 EA 200100662A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
integrity
intestinity
restoring
maintaining
Prior art date
Application number
EA200100662A
Other languages
Russian (ru)
Inventor
Сьюзн Мари Коп
Майкл Скотт Кэплан
Original Assignee
Американ Хоум Продактс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Американ Хоум Продактс Корпорейшн filed Critical Американ Хоум Продактс Корпорейшн
Publication of EA200100662A1 publication Critical patent/EA200100662A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C11/00—Milk substitutes, e.g. coffee whitener compositions
    • A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
    • A23C11/04—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing non-milk fats but no non-milk proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pediatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Описывается способ и готовая форма композиции для использования в данном способе для поддержания и улучшения восстановления целостности кишки у пациентов, нуждающихся в этом, причем способ включает введение пациенту композиции, включающей эффективное количество, по крайней мере, одной n-6 полинасыщенной жирной кислоты в сочетании, по крайней мере, с одной n-3 полинасыщенной жирной кислотой.Международная заявка была опубликована вместе с отчетом о международном поиске.Describes the method and the finished form of the composition for use in this method to maintain and improve the restoration of the integrity of the intestine in patients who need it, and the method includes the administration to the patient of a composition comprising an effective amount of at least one n-6 polyunsaturated fatty acid in combination with at least one n-3 polyunsaturated fatty acid. The international application was published along with an international search report.

EA200100662A 1998-12-15 1999-12-13 METHOD AND COMPOSITION FOR MAINTAINING AND RESTORING INTESTINITY INTEGRITY EA200100662A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11237498P 1998-12-15 1998-12-15
PCT/US1999/029478 WO2000035443A1 (en) 1998-12-15 1999-12-13 Method and composition for the maintenance and restitution of gut integrity

Publications (1)

Publication Number Publication Date
EA200100662A1 true EA200100662A1 (en) 2001-12-24

Family

ID=22343574

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100662A EA200100662A1 (en) 1998-12-15 1999-12-13 METHOD AND COMPOSITION FOR MAINTAINING AND RESTORING INTESTINITY INTEGRITY

Country Status (14)

Country Link
EP (1) EP1140063A1 (en)
JP (1) JP2002532420A (en)
KR (1) KR20020002361A (en)
CN (1) CN1330542A (en)
AR (1) AR021669A1 (en)
AU (1) AU3119600A (en)
BR (1) BR9916156A (en)
CA (1) CA2351469A1 (en)
EA (1) EA200100662A1 (en)
HU (1) HUP0104760A2 (en)
IL (1) IL143322A0 (en)
NO (1) NO20012947L (en)
PL (1) PL348810A1 (en)
WO (1) WO2000035443A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638416B1 (en) 2003-06-23 2013-05-01 Nestec S.A. Use of a nutritional formula for optimal gut barrier function
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US7303745B2 (en) 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
JP2007063219A (en) * 2005-09-01 2007-03-15 Juntendo Agent for preventing neonatal necrotizing enterocolitis
ES2558112T3 (en) * 2010-12-29 2016-02-02 Abbott Laboratories Nutritional products that include a new lipid system that includes monoglycerides
AU2015327027A1 (en) * 2014-09-30 2017-02-23 Société des Produits Nestlé S.A. Nutritional composition for use in promoting gut and/or liver maturation and/or repair
WO2023245470A1 (en) * 2022-06-22 2023-12-28 南方医科大学珠江医院 Use of mdp analog in preparing medicament for treating inflammatory bowel disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670285A (en) * 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
DE3603000A1 (en) * 1986-01-31 1987-08-06 Milupa Ag NEW FATTY MIXTURE OF POLYENIC ACID AND THEIR USE IN THE PRODUCTION OF INFANT FOODS
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
US5444054A (en) * 1994-04-01 1995-08-22 Abbott Labatories Method of treating ulcerative colitis
DE4417851C1 (en) * 1994-05-20 1995-10-05 Horst Heirler Dietary food with medium-chain fatty acids and its use
EP0711503A3 (en) * 1994-11-14 1997-11-26 Scotia Holdings Plc Milk fortified with GLA and/or DGLA
US5993221A (en) * 1997-05-01 1999-11-30 Beth Israel Deaconess Medical Center, Inc. Dietary formulation comprising arachidonic acid and methods of use

Also Published As

Publication number Publication date
WO2000035443A1 (en) 2000-06-22
CN1330542A (en) 2002-01-09
CA2351469A1 (en) 2000-06-22
AU3119600A (en) 2000-07-03
BR9916156A (en) 2001-09-04
IL143322A0 (en) 2002-04-21
WO2000035443A9 (en) 2000-12-07
JP2002532420A (en) 2002-10-02
EP1140063A1 (en) 2001-10-10
KR20020002361A (en) 2002-01-09
NO20012947D0 (en) 2001-06-14
HUP0104760A2 (en) 2002-04-29
PL348810A1 (en) 2002-06-17
AR021669A1 (en) 2002-07-31
NO20012947L (en) 2001-06-14

Similar Documents

Publication Publication Date Title
DK0731699T3 (en) Method of reducing body fat in animals by administration of conjugated linoleic acid
PT774962E (en) USING DHA AS A PHARMACEUTICAL COMPOSITION
DE69624768T2 (en) nutritional composition
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
ATE241323T1 (en) VIRTUAL ORTHODONTIC DENTAL TREATMENT
DK0880350T3 (en) Treatment of disseminated sclerosis
EE9900428A (en) Anti-cough formulations
IT1187687B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AS ACTIVE INGREDIENTS FLAVANOLIGNANI AND PHOSPHOLIPIDS
ATE258792T1 (en) HIGH LIPID DIET
BR9916860A (en) Method of reducing blood cholesterol and / or other blood glycerides in a mammal individual, preparation in the form of a dosage unit, and, set to orally administer the same
PT998287E (en) USES OF LEVOBUPIVACAINE
EA200100662A1 (en) METHOD AND COMPOSITION FOR MAINTAINING AND RESTORING INTESTINITY INTEGRITY
EA199800717A1 (en) METHOD FOR THE TREATMENT OF MAMMAL DISEASES AND THE CYVITTERION COMPOSITION
DE69534632D1 (en) CLORIMAZOLE METABOLITE IN THE TREATMENT OF SICKLE LEMENIA
EA199800866A1 (en) METHOD OF REMOVAL OF PAIN
PT980253E (en) SOMATOSTATIN AND SOMATOSTATIN AGONISTS TO TREAT INSULIN INSULIN AND X SYNDROME
HUP9903679A2 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating bipolar disorder
DE69734349D1 (en) TREATMENT OF BONE DRESS WITH ADRENOMEDULLIN
ATE335461T1 (en) SKIN PREPARATION
ATE306269T1 (en) TREATING EXCESSIVE AGGRESSIVENESS WITH OLNZAPINE
IL110888A (en) Pharmaceutical compositions for the treatment of liver diseases comprising a vasodilating compound
ATE164766T1 (en) COMPOSITION OF ASPHODELUS TO INCREASE THE NUMBER OF WHITE BLOOD CELLS
ATE345138T1 (en) METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING HEARTBURN
RU98102466A (en) METHOD FOR TREATING PATIENTS WITH OSTEOARTHROSIS
UA26886C2 (en) 1,3-diaryl-4,5-polymethylenimidazole salts, demonstrating analgesic activity